MARKET

AERI

AERI

Aerie Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.08
-0.21
-1.58%
After Hours: 13.08 0 0.00% 16:00 04/02 EDT
OPEN
13.23
PREV CLOSE
13.29
HIGH
13.53
LOW
12.80
VOLUME
855.93K
TURNOVER
--
52 WEEK HIGH
49.16
52 WEEK LOW
10.80
MARKET CAP
607.28M
P/E (TTM)
-2.9775
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AERI stock price target is 36.75 with a high estimate of 54.00 and a low estimate of 17.00.

EPS

AERI News

More
  • Gone: Triangle public companies lose $30 billion in value during 1Q 2020
  • American City Business Journals · 5h ago
  • Stifel Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $40
  • Benzinga · 1d ago
  • Healthcare Pro James Flynn Picks up These 3 Stocks on the Cheap
  • TipRanks · 03/25 15:18
  • Why Is Aerie (AERI) Down 40.5% Since Last Earnings Report?
  • Zacks · 03/21 16:30

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About AERI

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
More

Webull offers kinds of Aerie Pharmaceuticals Inc stock information, including NASDAQ:AERI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AERI stock news, and many more online research tools to help you make informed decisions.